HLS Therapeutics Inc.
HLTRF
$2.96
-$0.33-10.03%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 28.61% | 22.85% | 7.59% | -8.04% | -16.67% |
| Total Depreciation and Amortization | -28.87% | -27.55% | -20.99% | -13.97% | -7.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -40.10% | -37.81% | 7.51% | 26.32% | 38.18% |
| Change in Net Operating Assets | -77.35% | -45.75% | 168.94% | 190.33% | 225.60% |
| Cash from Operations | -49.31% | -45.22% | -13.66% | -17.48% | -6.81% |
| Capital Expenditure | 63.41% | 55.56% | 66.67% | -19.44% | 8.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 9,052.70% | 8,433.33% | 230.55% | 98.53% | 98.54% |
| Cash from Investing | 6,308.99% | 6,117.44% | 229.77% | 98.11% | 98.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -127.97% | -155.23% | -19.24% | 1.73% | 9.37% |
| Issuance of Common Stock | -- | -100.00% | -100.00% | -100.00% | -27.17% |
| Repurchase of Common Stock | 61.34% | 10.74% | -80.28% | -42.20% | -55.51% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 100.00% | 100.00% | 74.99% | 51.67% |
| Other Financing Activities | 12.43% | 12.43% | -299.22% | -196.24% | -112.83% |
| Cash from Financing | -59.60% | -65.66% | -226.49% | -133.15% | -113.52% |
| Foreign Exchange rate Adjustments | -424.63% | 1,340.00% | -10.66% | 106.84% | 168.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -465.83% | -906.81% | 5,180.26% | -22.14% | 369.52% |